As mentioned above, PD-L1 and PD1 are expressed on GIST cells and infiltrating T cells, respectively, and PD1/PD-L1 inhibitors may enhance the cytotoxicity of CD8+ T cells against GIST cells and thus improving patients’ prognosis. The gene discussed is CD8A; the disease is gastrointestinal stromal tumor.